Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

ACC 2026 | STEMI-Door To Unload: Unloading with Impella before PCI did not reduce infarct size in anterior STEMI

Anterior ST-segment elevation myocardial infarction (STEMI) remains associated with a high incidence of heart failure and mortality, even in the era of early reperfusion. The “door-to-unload” concept emerged as a physiologically appealing strategy, supported by preclinical data and a pilot study suggesting that left ventricular unloading prior to reperfusion could reduce infarct size.

Cobertura Científica SOLACI ACC 2026

The objective of the STEMI-DTU study was to evaluate whether a strategy using Impella CP, with a protocolized delay of at least 30 minutes before PCI, could reduce infarct size compared with a standard strategy of coronary angiography and immediate angioplasty in patients with acute anterior STEMI without cardiogenic shock.

This was a randomized study that included patients aged 18 to 85 years, with a first myocardial infarction, presenting between 1 and 6 hours from symptom onset, with anterior STEMI and anatomy suitable for Impella use. Patients were randomized to a strategy of Impella CP + ≥30-minute delay before PCI, with support for 4 to 24 hours, or to immediate PCI. The primary efficacy endpoint was infarct size measured by cardiac MRI between days 3 and 5, expressed as a percentage of left ventricular mass. A total of 527 patients were randomized across 55 centers.

The results showed that, in the intention-to-treat population, there were no differences in the primary endpoint: infarct size was 30.8±16.2% in the treatment group and 31.9±16.9% in the control group (95% CI -4.2 to 2.0; p=0.50). In the per-protocol analysis, no significant differences were observed either: absolute difference of -1.9% (95% CI -5.5 to 1.6; p=0.28). The hierarchical secondary endpoint also showed no benefit, with a win ratio of 1.04 (95% CI 0.84–1.28; p=0.73).

Read also: ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI.

As expected, the unloading strategy prolonged reperfusion times: there was an average increase of 47 minutes in total ischemic time and 42 minutes in door-to-balloon time, with no bailout PCI required. At 12 months, no significant differences were observed in all-cause mortality (4.0% vs 5.1%; HR 0.76; p=0.51).

Regarding safety, in the post hoc analysis of the ITT population, the composite of major bleeding or vascular complications was more frequent in the treatment group (34.0% vs 6.0%), mainly driven by access-site-related events (31.7% vs 2.3%).

Conclusions: STEMI-DTU Study Design: Impella CP with pre-PCI delay vs immediate angioplasty in anterior STEMI

The combination of Impella CP with a 30-minute delay before PCI did not reduce infarct size compared with immediate PCI in patients with anterior STEMI without shock. Major bleeding and vascular complications were more frequent in the Impella group.

Presented by Gregg W. Stone at the Late-Breaking Clinical Trials, ACC.26, March 28–30, New Orleans, USA.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Omar Tupayachi
Dr. Omar Tupayachi
Member of the Editorial Board of solaci.org

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

GLUCO-TAVI | Can Glucocorticoids Reduce the Need for Permanent Pacemaker Implantation After TAVI?

Despite the expansion of transcatheter aortic valve implantation (TAVI) indications, cardiac conduction disturbances (CCD) and the need for permanent pacemaker implantation (PPI) remain the...

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...